Histamine release in human subjects by modified gelatin (Haemaccel) and dextran: an explanation for anaphylactoid reactions observed under clinical conditions? by Lorenz, Wilfried et al.
Br.J. Anaesth. (1976), 48, 151
HISTAMINE RELEASE IN HUMAN SUBJECTS BY MODIFIED
GELATIN (HAEMACCEL) AND DEXTRAN: AN EXPLANATION
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SUMMARY
Histamine release by modified gelatin (Haemaccel) and dextran (Macrodex) has been demonstrated
in volunteers by direct and indirect methods. In a pilot study of Haemaccel, histamine release was
observed in six of seven volunteers. The highest plasma histamine concentration was 4.8 ng/ml, the
lowest 1.7 ng/ml: two of the subjects showed slight allergic reactions. Using Haemaccel batch 2551,
10 out of 12 subjects reacted to the rapid infusion of Haemaccel with increased plasma histamine
concentrations, whereas none reacted to Ringer's solution. None of the 10 subjects had an allergic
reaction, but an increase in gastric secretion was observed in eight. Changes in the venous basophil
granulocyte count were found in both those who reacted and those who did not react to Haemaccel.
After the rapid infusion of dextran the highest plasma histamine concentration was 5.0 ng/ml, the
lowest 1.3 ng/ml. The withdrawal of blood had no influence on plasma histamine concentration. The
incidences of histamine release produced by Haemaccel varied with different batches. Thus, it seems
unlikely that immunological mechanisms are principally responsible. Nine instances of allergic and
anaphylactoid reactions to plasma substitutes have been reported, seven after Haemaccel infusion,
and two after dextran administration. One of the patients who received dextran died. Histamine
release was always associated with Haemaccel infusion and corresponded in extent to the clinical
symptoms observed, but there was no significant histamine release associated with the reactions to
dextran.
Solutions containing dextran and gelatin have been
used in a wide variety of clinical situations (Bauer
and Ostling, 1970). These drugs may cause anaphylac-
toid and allergic reactions the explanation of which is
not clear. Adverse reactions to dextran (Brisman,
Parks and Haller, 1968; Strebel and Siegler, 1968;
Maddi, Wyso and Zinner, 1969; Carlsson et al.,
1972) and to gelatin (Eberlein and Dobberstein,
1962; Meisel and Zockler, 1971; Schmidt and
Pfluger, 1971; Miiller and Dietzel, 1972) have been
reported.
It has been shown that plasma substitutes release
histamine in animals (Giertz and Hahn, 1966;
Messmer et al., 1970; Goth, 1972; Lorenz, Barth,
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Karges et al., 1974; Lorenz, Barth, Thermann
et al., 1974; Lorenz, Thermann et al., 1974). How-
ever, there are differences between species. Dextran
liberates histamine in rats (Hahn and Wellmann,
1952) and rabbits (Haining, 1956), but not in dogs
(Messmer et al., 1970) and pigs (Lorenz, Barth et al.,
1971). Gelatin preparations increase whole-blood
histamine concentrations in dogs (Messmer et al.,
1970), but do not release histamine in guineapigs,
rats and rabbits (Keller, 1969; Schwick and Heide,
1969; Lorenz, W., unpublished data). Thus it is
uncertain whether the anaphylactoid reaction to
plasma substitutes in man is a result of histamine
release. We have reported previously on histamine
release in man by dextran and gelatin (Lorenz et al.,
1970; Lorenz, Doenicke et al., 1971; Lorenz,
Schmal et al., 1972; Seidel et al., 1973a), but it was
not known whether this was a result of chemical
histamine release from mast cells (Paton, 1956) or a
result of anaphylaxis (Bauer and Ostling, 1970;
Lorenz, Seidel et al., 1974).
The frequency of histamine release associated with
plasma substitutes in animals and man varies from
batch to batch, from species to species and even from
strain to strain (Giertz and Hahn, 1966; Messmer
et al., 1970; Seidel et al., 1973b; Lorenz, Seidel et al.,
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1974). In this report evidence for histamine release in
man by plasma substitutes has been obtained using
both chemical and biological techniques. The
incidence of histamine release was found to vary with
the batch used. Thus hypersensitivity is probably not
the main cause of these reactions.
MATERIALS AND METHODS
Materials
Volunteers and patient. Seventy-eight volunteers
and one patient were tested in 1969-73. There were
72 males and six females (69 medical students, three
technicians and six anaesthetists). The weight range
was 54-94 kg and the age range was 19-36 yr. None
of the volunteers had a history of allergy (asthma,
hay fever, or intolerance of medicaments or food-
stuffs (Mendez and Hughes, 1952)), pneumonia,
salmonellosis (Gropper, Raisz and Amspacher, 1952;
Kabat et al., 1957), collagen disease or gout (Maurer,
1954a, 1960). None had received dextran or gelatin
previously (Kabat and Bezer, 1958; Schwick and
Heide, 1969). The presence of pre-formed antibodies
to gelatin (Maurer, 1954b) and dextran, however,
was not tested. None of the subjects in whom gastric
secretion was to be measured had any history of
gastric disease.
Blood for plasma histamine determinations was
withdrawn and processed according to Lorenz,
Reimann and colleagues (1972).
Plasma substitutes. Dextran-60 (Macrodex, Knoll,
Ludwigshafen)and gelatin (Haemaccel,Behringwerke,
Marburg) were studied (table I). Gelatin contained
neither preservative agents (Schone, 1969) nor anti-
histaminic drugs (Lorenz, Barth, Karges et al., 1974).
Dextran, several batches of gelatin and Ringer's
solution (pH 6.0) were obtained from Munich
University pharmacy, and gelatin batches Nos. 2549,
2551, 2559, 3000, and V 183/1 directly from the
manufacturer. Batches 1786 (manufactured in June
1967), 2019 (July 1968), 2406 (November 1969), 2549
(April 1970), 2559 (May 1970) and 3000 (May 1972)
were on the market. Batches 2551 and V 183/1,
available for clinical trials only, were obtained from
the commercially available batches Nos. 2498 and
3214 by adsorption on charcoals (Supra Norit and
Carbopuron 4n, Degussa) at pH 9.0 and 7.0, respect-
ively. Batches 1786 and 2019 were prepared from
crude gelatin which contained fractions from various
stages of the extraction procedure; later batches
consisted of only the first fraction of crude gelatin
(Lorenz, Barth, Karges et al., 1974). The patient
received dextran-60 (Medac, Hamburg), batch R 614
which showed the same properties as dextran-60
(Macrodex) (table I).
Reagents and drugs. For the assay of plasma
histamine, reagents were used according to Lorenz
and colleagues (Lorenz, Reimann et al., 1972;
Lorenz, Barth, Thermann et al., 1974). Dextran did
not contain fluorescence-producing or -quenching
material whereas the interfering substances in all the
gelatin batches had to be eliminated by modified
reaction conditions (Lorenz, Reimann et al., 1972;
Lorenz, Barth, Karges et al., 1974; Lorenz, Barth,
Schmal et al., 1974; Lorenz, Barth, Thermann et al.,
1974; Lorenz, Thermann et al., 1974). The volunteers
received no drugs other than the plasma substitutes,
whereas the patient was treated with prednisolone
(Lentia, Munich) and clemastine (Sandoz, Basle).
These drugs did not interfere with plasma histamine
assay.
Infusion of plasma substitutes ("normovolaemic" haemo-
dilution) and methods
The experimental protocol guaranteed an approxi-
mately isovolaemic haemodilution, notwithstanding
Schmier's (1969) reservations. The subjects fasted for
at least 6 hr and the experiments were carried out
from 3 a.m. to 5 p.m. No medication was allowed
within the 36 hr immediately preceding the study. A
nasogastric tube was inserted under x-ray control to
permit aspiration of gastric secretion (Lorenz,
Doenicke et al., 1972a, b). E.c.g. leads and a sphygmo-
manometer cuff were applied. The subjects were
studied supine. A polyethylene cannula was inserted
into a superficial vein in the left arm for blood
sampling. Blood was withdrawn from the right arm
and plasma substitutes were infused by the same
route.
Fifteen minutes after the preparations had been
completed, blood for baseline plasma histamine assay
and, thereafter, 500 ml of blood were withdrawn
(approx. 2 ml/kg/min). Thirty seconds later a sample
for histamine determination was taken and 500 ml of
the plasma substitute was infused under pressure
(approx. 2 ml/kg/min, 37 °C). At 1, 5, 10, 20 and
30 min after the end of the infusion further samples
for histamine assay were taken.
Histamine in human plasma was determined
nuorimetrically using the method of Lorenz,
Reimann and colleagues (1972). For each series of
reaction mixtures, two reagent blanks and one
revised blank were used. Two determinations of
recovery after the addition of authentic histamine
6 ng were performed daily and were found to be
 a
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TABLE I. Origin, preparation and some physico-chemical properties of the clinical dextran
and gelatin used in this communication
Properties of the
substances
Origin
Preparation
Linkages
Weight average of
molecular weight
(Mw)
Number averageJ
of molecular
weight (Mn)
Range of molecular
weight
Viscosity
Concentration
Solvent
pH (units)
Clinical batches
used in this
communication
Dextran*
Saccharose
Bacterial biosynthesis using
Streptococcus leuconostoc
mesenteroides N R R L B 512 F ,
precipitation by alcohols.
partial acid hydrolysis,
fractionation by ethanol
>93% a-l,6-glycosidic
60 000
32 000
20 000-95 000 (80%)
0.23
(intrinsic viscosity rj)
60 g/litre
0.9% saUnet
7.0-7.1
K 169, 3262 A 3
Gelatin f
Bovine ossein
Partial heat degradation
of the native gelatin,
crosslinking of peptides
(mol. wt. x 12 000) by
hexamethylene diisocyanate
Reaction of a-amino,
imidazole and e-amino
groups with hexamethylene
diisocyanate
35 000
24 500
5000-50 000 (90%)
1.7-1.8
(relative viscosity, H2O =1)
35 g/litre
Ringer's solution
7.2-7.3
1786, 2019, 2406, 2549, 2551,
2559, 3000, V 183/1
The data were obtained from: *Gruber, 1968; Appel, 1972; fSchone, 1969; tStoll and Nitschmann, 1969.
between 60 and 70%. Plasma histamine was expressed
as histamine base ng/ml plasma.
Gastric secretion, heart rate, arterial pressure and
the number of leucocytes, eosinophils and basophil
granulocytes in venous blood were determined by
methods described previously (Lorenz, Doenicke
et al., 1972a, b). In subjects who showed allergic and
anaphylactoid reactions after gelatin or dextran
infusion, a cutaneous prick test was performed
(Lorenz, Doenicke et al., 1972b). The test included
Haemaccel together with the gelatin hydrolysate
before cross-linking with hexamethylene diisocyanate.
Evaluation of histamine release and statistical methods
In contrast to dextran-60, the various gelatin
batches were administered in a random sequence
according to Goldstein, Aronow and Summer (1969).
Haemaccel batch 2551 was tested against Ringer's
solution, batch 1786 against batch 2019, and 2549
and batch 3000 against V 183/1 in a double-blind
pilot study.
The criteria for histamine release under clinical
conditions have been denned previously (Lorenz,
Thermann et al., 1974). They include the demon-
stration of a histamine clearance curve in plasma,
determination of histamine concentrations of more
than 1 ng/ml in plasma and confirmation by bio-assay
of the fluorimetric measurements such as gastric
secretion, heart rate or arterial pressure. By these
criteria reacting and non-reacting individuals were
identified. The incidence of histamine release by the
plasma substitutes was determined for each batch of
these solutions. It was defined as the number of
reacting subjects per number of subjects receiving the
substance.
In comparing groups both the t test and the
Wilcoxon test for paired samples were used. The
X2 test was used for testing the incidences of histamine
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TABLE II. Histamine release by Haemaccel in human subjects (pilot study)
T7»cr
subject
Non-reacting:
1
Reacting:
2
3
4
5
6
7
Mean ±SD
Plasma histamine concentration (ng/ml)
bleeding
0.5
0.6
0.5
0.9
0.6
1.0
0.9
0.75
±0.2
infusion
0.2
0.6
0.4
0.7
0.8
1.2
0.6
0.7(a)
±0.3
After infusion of Haemaccel
1 min
0.3
1.7
1.8
2.2
3.2
3.3
4.0
2.7""
±0.9
5 min
0.4
1.1
1.4
2.2
3.3
4.3
4.8
2.85
±1.5
10 min
0
0.6
1.0
1.1
1.8
2.0
2.1
1.4
±0.6
Single values obtained from seven test subjects. Mean ±SD was
calculated for the reacting subjects. Statistical significance in the t test for
paired data: a/b, P<0.02; in the Wilcoxon test a/b, P<0.05.
release after the infusion of different batches of the
plasma substitutes (Snedecor and Cochran, 1967).
RESULTS
Plasma histamine concentrations in test subjects
following rapid infusion of Haemaccel {pilot
study)
In a pilot study (August 1969) Haemaccel obtained
from the University Pharmacy, Munich, was infused
into seven test subjects. Since we did not know at this
time that the histamine-releasing activity of this
plasma substitute probably depended on the batches
used, the batch numbers were not noted, but would be
less than 2406, which was produced in November
1969 (see Materials). Histamine release was observed
in six of the seven test subjects (table II). The plasma
histamine concentrations in this series were in the
range 1.7-4.8 ng/ml. No changes in heart rate or in
arterial pressure occurred, whereas skin reactions
were observed in two test subjects (Nos. 6 and 7,
table IV).
Plasma histamine concentrations following rapid infusion
of Haemaccel, dextran and Ringer's solution
{known batches)
Haemaccel (batch 2551) which was obtained from
the manufacturer for clinical trials caused a high
frequency of histamine release (fig. 1). Ten out of 12
individuals had an increase in plasma histamine
concentration although they did not show any
significant histamine release following the infusion of
Ringer's solution. The rapid loss of 500 ml of blood
2.0
[ng/ml]
Tn
•£ o.sJ
Batch 2551
O-O n = 2
A " ~ A n =12
(Ringer)
Bleeding Infusion
10 20
Time fminT
FIG. 1. Histamine release in human subjects by rapid
intravenous infusion of gelatin (Haemaccel). Mean values
± SEM. • • subjects reacting to Haemaccel by
elevated plasma histamine concentrations according to the
criteria described in Materials and Methods. O O
non-reacting subjects. B.B. and B.I.: values from samples
taken before bleeding and before infusion, respectively. For
further conditions see Materials and Methods. Statistical
significance in the t test for paired data. B.I./I min,
P<0.001; B.I./5min, P<0.001. Wilcoxon test in both
cases P < 0.01. All these values refer to the reacting subjects.
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did not alter the plasma histamine concentration. The
histamine release did not cause clinically detertable
effects in any subject. The plasma histamine concen-
trations were in the range 1.6-3.0 ng/ml.
Haemaccel
batch No 2551
• — • n. 2
A ^ A n * 1 0
(Ringer)
I
20 30
Time TminJ
2O 30
Time QninJ
FIG. 3. Gastric acid secretion in human subjects following
rapid infusion of Haemaccel and of Ringer's solution. Mean
values + SEM. • • subjects reacting to Haemaccel by
an elevation of the plasma histamine concentrations.
O • non-reacting subjects. A A subjects receiving
Ringer's solution (the same test persons, who were also
at U
niversitaetsbibliothek R
egensburg on A
ugust 22, 2011
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after the administration of dextran differed, however,
from those after gelatin. The maximum histamine
release was observed lOmin after the dextran
infusion, and the increase in plasma histamine lasted
more than 30 min. Following gelatin infusion, the
maximum histamine liberation occurred after 1-5 min
and normal plasma histamine concentrations occurred
as early as 20 min later. The effect of gelatin corre-
sponded more closely to that of other histamine
liberators such as compound 48/80.
Biological reactions in human subjects to histamine
release by gelatin and dextran
For technical reasons only 10 of the 12 test subjects
who received Haemaccel, batch 2551, underwent
measurements of gastric secretion (fig. 3), blood
leucocyte count, heart rate and arterial pressure
(fig- 4).
No stimulation of gastric secretion occurred in these
two subjects, who showed no increased histamine
concentrations after gelatin administration (fig. 3).
Neither the withdrawal of blood nor the rapid
infusion of Ringer's solution affected gastric secretion
to any great extent. In the test subjects who reacted
to Haemaccel with increased plasma histamine
concentrations, however, the acid output increased by
more than 600% (fig. 3). At the time of maximum
stimulation the acid output corresponded to nearly
half of the maximum gastric secretion which in turn
corresponded to plasma histamine concentrations of
3-4 ng/ml in histamine infusion experiments (Lorenz,
Doenicke et al., 1972a, b).
The venous leucocyte count showed characteristic
changes after Haemaccel infusion (fig. 4), but was
similar in reacting and non-reacting subjects. Thus it
may be independent of histamine release. Therefore
the determination of histamine liberation by whole-
blood histamine assay, which depends on the basophil
count, is not justified (Lorenz, Doenicke et al., 1972a;
Lorenz, Reimann et al., 1972). Bleeding alone and
Ringer's solution did not alter the leucocyte count
(fig- 4).
Gastric secretion and leucocyte concentrations were
not determined in subjects who received dextran.
Heart rate and arterial pressure were not altered
significantly by the infusion of Haemaccel, Ringer's
solution (fig. 4) or dextran with the exception of
one subject who reacted to Macrodex with an
anaphylactoid reaction without histamine release
(see below). These results are in agreement with
findings obtained during histamine infusion in man
(Lorenz, Doenicke et al., 1972a, b).
Haemaccel batch 2551
9 reacting subjects
Onon reacting subjects
71 Ringer
[cells]
rwi
mmL
 -
1
t t
Systolic pressure
Oiastolic pressure
20 30
Time [mini
FIG. 4. Effect of Haemaccel and Ringer's solution on
leucocyte concentration, heart rate and arterial pressure in
human subjects. Mean values +SEM. • • subjects
reacting to Haemaccel by an elevation of the plasma
histamine concentrations. O O non-reacting subjects.
O • subjects receiving Ringer's solution. For heart
rate and arterial pressure the values obtained after infusion
of Ringer's solution were not shown, because they were
situated just within the range of those obtained after
infusion of Haemaccel. B.B. = before bleeding, B.I. =
before infusion. For further comments and conditions see
figure 1 and Materials and Methods. Statistical significance
in the Wilcoxon test: B.B./l min, /><0.01 for leucocytes,
eosinophilic and basophilic granulocytes of the subjects
receiving Haemaccel.
Incidence of histamine release in human subjects
following infusion of various batches of plasma
substitutes
The incidence of the reactions to Haemaccel
(increase in acid output following administration of
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Gastric acid secretion and basophils in man 60
following rapid infusion of different batches
of gelatin 4 0 .
Gastric secretion
•
O
cells
/<-litre
- •
-o
reacting
non-react ing
m-equiv
mm
Basophils
I ^ B reacting
LJ " " D non.reacting
Batch 2O19
60. 0.3. 60. 0.3.
4 0. 0.2.
3 0
FIG. 5. Gastric acid secretion and basophilic granulocyte concentrations in the venous blood of
human subjects following rapid infusion of different batches of Haemaccel. Mean values ± SEM.
• • ( • • ) subjects reacting to Haemaccel by an increased acid output; O O
(• D) non-reacting subjects. B.B. = before bleeding, B.I. = before infusion. For further
conditions see figure 1 and Materials and Methods.
the plasma substitute) varied from batch to batch
(fig. 5). Because of the limited number of subjects, the
differences were not statistically significant in this
series of experiments (table III). The two subjects
reacting to Haemaccel batch 1786 by an increased
acid secretion showed also symptoms of an "allergic"
reaction which are described in table IV.
In a double-blind pilot study in which five subjects
received Haemaccel batch 3000 and five received
Haemaccel batch V 183/1, none who received the first
batch showed any reaction, whereas two showed
considerable anaphylactoid reactions with the second
batch. Because of these two reactions (table IV) the
pilot study was discontinued. Since both Haemaccel
batches 2551 and V 183/1, which were treated with
charcoal, were associated with high incidences of
histamine release (table III) charcoal adsorption is not
recommended for clinical use.
The findings following infusion of Haemaccel and
dextran are presented in table III. The varying, and
in some cases high, incidences of histamine release,
depending on the batches used, would suggest that the
histamine response to Haemaccel is not the result of
an immunological process, but a chemical action on
mast cells or basophils, or both.
Anaphylactoid and allergic reactions to Haemaccel and
dextran in human subjects
In eight out of 78 subjects, anaphylactoid and
allergic reactions occurred following the rapid
infusion of 500 ml of plasma substitutes. Table IV
shows the responses to Haemaccel. In four volunteers,
plasma histamine concentrations were measured, but
in three subjects histamine release could be demon-
strated only indirectly by measuring gastric secretion,
and by observing tachycardia and hypotension. The
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TABLE I I I . Incidence of histamine release in man by different batches of gelatin and dextran,
measured by an increase of gastric acid secretion or by increased plasma histamine concentrations
Macromolecular
substance
Gelatin
Haemaccel
Dextran
Macrodex
Batch
no.
1786
2019
2549
2551
3000
V 183/1
K169
3262/A3
Incidence of histamine release •
Gastric secretion
»iln2
2/7
3/8
5/8
8/10
—
—
—
—
Maximum
value observed
(m-equiv/min)
0.32
0.20 + 0.2
0.21+0.8
0.26±0.12
—
—
—
—
Plasma histamine
concentration
Maximum
value observed
njn2 (ng/ml)
— —
— —
— —
10/12 1.9 + 0.3
0/5 0.2
2/5 6.2
2/10 2.3
6/15 2.2 ±0.9
Mean values ±SD; n1 = number of subjects reacting to Haemaccel by histamine
release: n2 = number of subjects investigated. The maximum values are the maximum
response. Statistical significance {x
2 test) Batch 1786/2551 x2 = 2.53, P<0.2; 2551/3000
X2 = 7.5, P<0.01. The last two batches were assessed in different trials, but the experi-
ments were performed in the same room under the same experimental conditions by the
same observers.
increase in acid output, especially in subject No. 5,
was considerable and corresponded to plasma
histamine concentrations of about 6-10 ng/ml
(Lorenz, Doenicke et al., 1972a, b). In all who had
plasma histamine concentrations of 5 ng/ml or more
after the infusion of Haemaccel (or the corresponding
increase in acid secretion), an increase in heart rate
accompanied the increase of histamine concentration
(fig. 6). The arterial pressure was a less sensitive index
than heart rate: hypotension did not occur in subject
No. 1 (table IV), but was just measurable in subjects
Nos. 2 and 5 (table IV).
In contrast to Haemaccel, the two anaphylactoid
reactions to dextran described in this communication
seemed not to be mediated by a release of histamine
(table V). One of the reactions occurred in a volunteer
and one in a patient.
The patient who died following dextran was a
69-year-old man who was undergoing surgery for
occlusion of the right common iliac artery. Pre-
medication was atropine 0.01 mg/kg and dimen-
hydrinate 1.5 mg/kg. At least 15 min later, dextran-60
was infused slowly. About 3 min later (when only
20 ml had been given) a severe anaphylactoid reaction
occurred (table V). The patient died, and the post-
mortem findings were normal (no pulmonary
embolism or myocardial infarction). The bottle
containing the residue of the plasma substitute was
sent to the University's pharmacy and was found to be
free from bacteria and pyrogens.
Two samples of heparinized venous blood were
obtained 5 min after cardiac arrest, while external
cardiac massage was being performed. One minute
later the blood specimens were centrifuged at 0-4 °C,
and plasma was prepared. Plasma histamine concen-
trations were determined simultaneously in one of
the patient's samples and in those of two normal
individuals, while histamine was added to the other
sample from the patient in order to test its recovery
and to detect any interference in the assay from
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FIG. 6. Correlation between plasma histamine concentration, heart rate and arterial pressure in three
cases of an anaphylactoid and allergic reaction to Haemaccel and Alacrodex. Single values from each
of the test subjects. • • plasma histamine concentration (ng/ml), [III systolic and diastolic
arterial pressure (mm Hg) and • • heart rate (beats/min). B.B. = before bleeding, B.I. =
before infusion. For further conditions see Materials and Methods.
No severe or life-threatening anaphylactoid reaction gastric acid secretion. An intrinsic antihistaminic
was observed in the test subjects. Some clinical activity against H1-receptors (Black et al., 1972) and
symptoms (in cases 1 and 5, table IV) were found to be both activating and inhibiting effects on histamine
less pronounced than expected from the relatively methyltxansferase3 the enzyme which inactivates
high plasma histamine concentrations and the strong mainly histamine in human subjects, was demon-
D
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TABLE V. Anaphylactoid reactions in human subjects following infusion of dextran-60
Plasma histamine
concentration (ng/ml)
Patient
no.
Dextran-60
batch no. Clinical observations and symptoms
Before After
infusion infusion
1 Dextran-60 After slow infusion of about 20 ml of dextran (within approximately Not tested 0.5
(O. A.) Medac 3 min): dizziness, feeling of weakness, generalized erythema. 2 min
R 614 later: weals on the neck and thorax, cyanosis, bronchospasm. The
infusion was stopped. Ringer and bicarbonate solution were
administered together with oxygen, cortisone 2 mg/kg, calcium
gluconate 10 mg/kg, clemastine 0.03 mg/kg and orciprenaline
0.06 mg/kg. 5 min later pulse not palpable, arterial pressure not
measurable, but e.c.g. normal. 2 min later cardiac arrest. Despite
external cardiac massage, electrical defibrillation, administration of
bicarbonate, cortisone, orciprenaline, the patient died
2 Macrodex 3 min after the beginning of infusion erythema on the face, hot feeling, 1.2 1.8
(J. D.) 3262/A 3 swelling in the nose. 2 min after the end of infusion weals on the
neck and the thorax, bronchospasm. 5 min later: oxygen given.
1 min thereafter prednisolone 1 mg/kg and clemastine 0.025 mg/kg
were injected i.v. and the bronchospasm disappeared within a few
minutes. 30 min later: the test subject still complained of pain in the
chest and feeling cold. Mild tachycardia but no hypotension
Single values from each of the subjects. The sample for testing the plasma histamine concentration in the patient was
obtained 5 min after cardiac arrest when external cardiac massage was already in progress. The sample from patient no. 2
(test subject) was obtained 1 min after the end of the rapid infusion of dextran. For further conditions see Materials and
Methods.
strated in Haemaccel (Lorenz, Barth, Karges et al.,
1974; Lorenz, Barth, Schmal et al., 1974). Thus this
plasma substitute may modify considerably the
effects of the histamine released by itself: the
activation of the enzyme may increase the elimination
velocity for high concentrations of histamine, as
was shown for another Hj-receptor antagonist,
dimethpyrindene (Lorenz, Thermann et al., 1974).
It may, however, enhance the effects of released
histamine at the H2-receptors, that is those responsible
for vasodilatation in the face (erythema) and for the
increase of heart rate (Wyllie, Hesselbo and Black,
1972), as was the case with dimethpyrindene (Lorenz,
Thermann et al., 1973). By its Hj-receptor antagonist
activity, Haemaccel may diminish the effects of
released histamine at the H^receptors, which are
responsible mainly for arterial hypotension, broncho-
spasm and intestinal motility.
In animal experiments it was shown that Haemaccel
released histamine in the dog mainly from the skin of
the upper half of the body and from the liver (Lorenz,
Doenicke et al., 1971; Lorenz, Thermann et al.,
1974). In human subjects the liver was a poor source
of histamine in all but a few of the 33 individuals
tested (Lorenz, Matejka et al., 1973; Lorenz, Seidel
et al., 1974). Thus the clinical symptoms following
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histamine release by Haemaccel at present may be
explained by the specific biochemical and pharma-
cological actions of this plasma substitute on the
histamine system. Allergic reactions were reported
relatively frequently, but severe anaphylactoid
incidents with marked hypotension and broncho-
spasm were rare (Eberlein and Dobberstein, 1962;
Bark, 1964; Gasparetto, Giron and D'Amigo, 1965;
Bortoluzzi et al., 1967; Meisel and Zockler, 1971;
Miiller and Dietzel, 1972; Lorenz, Doenicke et al.,
1973; Lund, 1973; Schoning, Krahl and Koch,
1973; Lorenz, Seidel et al., 1974).
In this report, histamine release by dextran has
been demonstrated in human subjects for the first
time, but the two anaphylactoid reactions, which were
observed in one patient and in one test subject, were
not accompanied by a significant histamine release.
Thus, it would appear that anaphylactoid reactions to
dextran do not have to be caused by histamine release,
although this mechanism cannot be excluded in all of
the cases reported in the literature, since dextran did
indeed release histamine in some of our volunteers.
The clinical symptoms, however, which have been
described in reports on anaphylactoid reactions to
dextran, differ from those observed after infusion of
Haemaccel (Maycock, 1952; Tarrow and Pulaski
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1953; Wilkinson and Storey, 1953; Tarrow, 1955;
Wilkinson, 1956; Henley, McPhaul and Albert,
1958; Thorsen, 1959; Thompson, 1960; Meissner,
1961; Shepherd and Vandam, 1964; Simone, 1965;
Bailey et al., 1967; Brisman, Parks and Haller, 1968,
1971; Maltby, 1968; Michelson, 1968; Strebel and
Siegler, 1968; Maddi, Wyso and Zinner, 1969;
Kohen et al., 1970; Schobinger, 1970; Carlsson et al.,
1972; Schoning, Krahl and Koch, 1973). An increased
intestinal motility with defaecation, rapidly develop-
ing and often severe hypotension and bronchospasm
are dominant in the clinical picture, whereas skin
reactions are not reported very frequently. Thus it
may be assumed that anaphylactoid reactions to
dextran in man are not usually caused by histamine
release, which is in contrast to the effect of Haemaccel.
Other vasoactive substances, such as kinins, pros-
taglandins and the slow-reacting substance A, have
to be investigated as possible causes of these clinical
incidents. It should be emphasized that even in true
anaphylactic reactions histamine is not necessarily
released in significant amounts as one of the mediators
of the second phase of the immune response. There
are examples in rats (Austen and Humphrey, 1963)
and sheep (Alexander et al., 1970), which would
indicate the greater importance of serotonin, kinins
and slow-reacting substance A in such patho-
physiological reactions.
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LIBERATION DE L'HISTAMINE DANS DES
SUJETS HUMAINS PAR LA GELATINE
MODIFIEE (HAEMACCEL) & DEXTRAN:
EST-CE UNE EXPLICATION DES REACTIONS
ANAPHYLACTOIDES OBSERVEES DANS
DES CONDITIONS CLINIQUES ?
RESUME
II a ete demontre' sur des volontaires, par des m6thodes
directes et indirectes, que la gelatine modified (Haemaccel)
et le dextran (Macrodex), liberent de Phistamine. Au cours
d'une etude pilote de PHaemaccel, la liberation d'histamine
a £te observee dans le cas de six volontaires sur sept. La
forte concentration d'histamine dans le plasma a 6te de
4,8 ng/ml, la plus faible de 1,7 ng/ml et deux sujets ont
accuse de 16geres reactions allergiques. Lorsqu'on a utilise
de l'Haemaccel—lot 2551—10 sujets sur 12 ont r£agi a
l'infusion rapide d'Haemaccel par des concentrations plus
importantes d'histamine dans le plasma, alors qu'aucun
d'entre eux n'a reagi a la solution de Ringer. Aucun de ces
dix sujets n'a eu reaction allergique, mais on a observe sur
huit d'entre eux une augmentation de la secretion gastrique.
On a trouve des changements dans la numeration des
granulocytes basophiles veineux aussi bien chez les
personnes qui ont eu des reactions que chez celles qui n'ont
pas reagi a l'Haemaccel. Apres une infusion rapide de
dextran, la concentration la plus forte d'histamine dans le
plasma a 6te de 5,0 ng/ml, et la plus faible: 1,3 ng/ml. Le
prelevement de sang n'a eu aucune influence sur les con-
centrations d'histamine dans le plasma. L'incidence des
liberations d'histamine produites par l'Haemaccel a varie
suivant les lots utilises. II semble done improbable que les
mecanismes d'immunologie soient les principaux respons-
ables de cet etat de choses. On a signal^ neuf cas de reactions
allergiques et anaphylactoides aux substituts du plasma:
sept apres une infusion d'Haemaccel et deux apres Padmin-
stration de dextran. L'un des patients auquel on avait
administre' du dextran est mort. La liberation d'histamine
a toujours 6te associee aux infusions d'Haemaccel et a corre-
spondu, en importance, aux symptomes cliniques observes,
mais il n'y a eu aucune liberation significative d'histamine
associee aux reactions au dextran.
FREIGABE VON HISTAMIN IM MENSCHEN,
DURCH MODIFIZIERTE GELATINE
(HAEMACCEL) UND DEXTRAN: EINE
ERKLARUNG FUR ANAPHYLAKTOIDE
REAKTOINEN, BEOBACHTET UNTER
KLINISCHEN BEDINGUNGEN?
ZUSAMMENFASSUNG
Freigabe von Histamin durch modifizierte Gelatine
(Haemaccel) und Dextran (Macrodex) wurde bei frei-
willigen Versuchspersonen durch direkte und indirekte
Methoden demonstriert. In einer richtungweisenden
Untersuchung des Haemaccel wurde die Freigabe von
Histamin bei sechs der sieben Freiwilligen beobachtet. Die
hochste Plasma-Histaminkonzentration war 4,8 ng/ml, die
niedrigste 1,7 ng/ml: zwei der Versuchspersonen zeigten
leichte allergische Reaktionen. Bei Verwendung von
Haemaccel-Satz 2551 reagierten 10 der 12 Versuchspersonen
auf die rapide Verabreichung von Haemaccel mit erhShten
Plasma-Histaminkonzentrationen, wogegen niemand auf
Ringers Losung reagierte. Keine dieser 10 Versuchspersonen
zeigte allergische Reaktionen, aber bei acht kam es zu einer
verstarkten gastrischen Sekretion. Veranderungen in der
Anzahl ven6ser basophiler Granulozythen ergaben sich bei
alien Versuchspersonen. Nach rapider Verabreichung von
Dextran betrug die hochste Plasma-Histaminkonzentration
5,0 ng/ml, die niedrigste 1,3 ng/ml. Die Entnahme von
Blut hatte keinen Einfluss auf diese Konzentrationen. Die
Freigabe von Histamin variierte je nach den verschiedenen
Satzen von Haemaccel, die verwendet wurden. Es ist daher
unwahrscheinlich, dass immunologische Mechanismen
dafur verantwortlich sind. Neun Falle von allergischen und
anaphylaktoiden Reaktionen auf Plasmasubstitute, sieben
nach Haemaccel-Verabreichung und zwei nach Dextran-
Verabreichung wurden gemeldet. Einer der Patienten starb
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nach der Verabreichung von Dextran. Die Freigabe von
Histamin war stets mit der Verabreichung von Haemaccel
verbunden, und entsprach dem Ausmass nach den beobach-
teten klinischen Symptomen, doch gab es keine signifikante
Freigabe von Histamin im Zusammenhang mit den Reak-
tionen auf Dextran.
DESCARGA DE HISTAMINA POR GELATINA
MODIFICADA (HAEMACCEL) Y DEXTRANO
EN EL HOMBRE: UNA EXPLICACION
DE LAS REACCIONES OBSERVADAS EN
CONDICIONES CLINICAS
SUMARIO
La descarga de histamina por gelatina modificada
(Haemaccel) y dextrano (Macrodex) ha quedado demostrada
en voluntarios por metodos directos e indirectos. En un
estudio piloto del Haemaccel, se advirtio una descarga de
histamina en seis o siete voluntarios. La mayor concen-
tration histaminica de plasma fue de 4,8 ng/ml, la menor de
l,7ng/ml: dos de los pacientes mostraron reacciones
alergicas ligeras. Con el uso de Haemaccel lote 2551,10 de los
12 pacientes reaccionaron a la rapida infusion de Haemaccel
con un incremento de concentraciones histaminicas de
plasma mientras que ninguno reaccion6 a la solution de
Ringer. Ninguno de los 10 pacientes sufrio una reaction
alergica, pero se observo en ocho de ellos un aumento
en la secretion gastrica. Se hallaron cambios en la medida
de los granulocitos basofilicos en las venas, tanto en los que
reaccionaron como en los que no reaccionaron al Haemaccel.
Despues de la rapida infusion de dextrano la mayor con-
centration histaminica de plasma fue de 5,0 ng/ml; la
menor fue de 1,3 ng/ml. La extraction de sangre no tuvo
influencia en la concentration histaminica de plasma. Las
incidencias de descarga de histamina producida por el
Haemaccel variaron segiin los diferentes lotes. Asi pues, no
parece probable que los mecanismos inmunologicos sean
mayormente los responsables. Se han reseflado nueve
casos de reacciones alergicas y anafilactoides a sustitutos
del plasma, siete despues de una infusion de Haemaccel y
dos despues de la administration de dextrano. Uno de los
pacientes que recibio dextrano murio. La descarga de
histamina estuvo siempre relacionada con la infusion de
Haemaccel y correspondio en extension a los sintomas
clinicos que se advirtieron, pero no hubo una descarga de
histamina significante relacionada con las reacciones al
dextrano.
 
